AI English summary of an SEC filing — figures as filed

Lilly said Dr. Marschall S. Runge notified its Board of Directors on August 13, 2024 of his decision to retire from the board, effective August 31, 2024.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Aug 16, 2024Period of report Aug 13, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

Lilly said Dr. Marschall S. Runge notified its Board of Directors on August 13, 2024 of his decision to retire from the board, effective August 31, 2024.
The company said Dr. Runge's decision to retire as a director did not arise from any disagreement with the company on any matter relating to its operations, policies or practices.
Eli Lilly said Dr. Runge has served on the board since 2013 as an independent director and as a member of the Science and Technology Committee and the Ethics and Compliance Committee.
The company said Dr. Runge brought expertise as a physician and scientist in areas including clinical trial design and patient safety, and that Chair and CEO David A. Ricks thanked him for his contributions over the last 10 years.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Runge Board Retirement Notice and Effective Date

Lilly said Dr. Marschall S. Runge notified its Board of Directors on August 13, 2024 of his decision to retire from the board, effective August 31, 2024.

Source · Based on the filing body and exhibits

Retirement reason and any disagreement with the company

The company said Dr. Runge's decision to retire as a director did not arise from any disagreement with the company on any matter relating to its operations, policies or practices.

Source · Based on the filing body and exhibits

Dr. Runge's Board Tenure and Committee Service

Eli Lilly said Dr. Runge has served on the board since 2013 as an independent director and as a member of the Science and Technology Committee and the Ethics and Compliance Committee.

Source · Based on the filing body and exhibits

Dr. Runge's Background and Ricks's Tribute

The company said Dr. Runge brought expertise as a physician and scientist in areas including clinical trial design and patient safety, and that Chair and CEO David A. Ricks thanked him for his contributions over the last 10 years.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.